Transgene SA – LSE:0OCQ.L

Add to watchlist

EUR 3.04

+2.32

+327.57%

Market closed

Open in about 19 hours

-34.77%

month

-34.77%

quarter

-46.94%

year

Market Cap	93.42M
Enterprise value	N/A

P/E	N/A
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	N/A
PEG ratio	N/A
EPS	-0.33

Revenue	5.13M
EBITDA	-48.02M
Income	-33.49M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	-935.43%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Transgene SA (LSE:0OCQ.L): Profit margin
Mar 2023	2.38M	-7.95M	-333.87%
Jun 2023	1.15M	-15.90M	-1375.61%
Sep 2023	1.56M	-3.21M	-204.85%
Dec 2023	28K	-6.42M	-22950%

Transgene SA Financials Estimate

Q Y

Transgene SA (LSE:0OCQ.L): Analyst Estimates
2027	68.1M	-59.34M	-87.15%

Analysts Price target
Financials & Ratios estimates

Transgene SA (LSE:0OCQ.L): Debt to assets
Mar 2023	49550000	27.59M	55.68%
Jun 2023	49550000	27.59M	55.68%
Sep 2023	45217000	29.60M	65.47%
Dec 2023	45217000	26.51M	58.64%

Transgene SA (LSE:0OCQ.L): Cash Flow
Mar 2023	-8.83M	8.94M	-457K
Jun 2023	-17.66M	17.89M	-914K
Sep 2023	-8.50M	8.33M	6.14M
Dec 2023	-17.30M	16.67M	12.58M

Transgene SA alternative data

Transgene SA (LSE:0OCQ.L): Employee count
Aug 2023	146
Sep 2023	146
Oct 2023	146
Nov 2023	146
Dec 2023	146
Jan 2024	146
Feb 2024	143
Mar 2024	143
Apr 2024	143
May 2024	141
Jun 2024	141
Jul 2024	141

Status	Patent	Filling date	Issue date
Application	Application M2-DEFECTIVE POXVIRUS Filling date: 27 Dec 2019 Issue date: 24 Feb 2022	27 Dec 2019	24 Feb 2022
Application	Application NOVEL ANTIBODIES AND NUCLEOTIDE SEQUENCES, AND USES THEREOF Filling date: 3 Sep 2019 Issue date: 10 Feb 2022	3 Sep 2019	10 Feb 2022
Application	Application COMBINATION OF ONCOLYTIC VIRUS WITH IMMUNE CHECKPOINT MODULATORS Filling date: 5 Aug 2020 Issue date: 3 Dec 2020	5 Aug 2020	3 Dec 2020
Grant	Grant Utility: Combination of oncolytic virus with immune checkpoint modulators Filling date: 16 Jul 2015 Issue date: 8 Sep 2020	16 Jul 2015	8 Sep 2020
Grant	Grant Utility: Fusion of heterooligomeric mycobacterial antigens Filling date: 9 Jan 2015 Issue date: 8 Sep 2020	9 Jan 2015	8 Sep 2020
Application	Application ONCOLYTIC VIRUS FOR EXPRESSION OF IMMUNE CHECKPOINT MODULATORS Filling date: 23 Dec 2019 Issue date: 25 Jun 2020	23 Dec 2019	25 Jun 2020
Grant	Grant Utility: Oncolytic virus for expression of immune checkpoint modulators Filling date: 16 Jul 2015 Issue date: 11 Feb 2020	16 Jul 2015	11 Feb 2020
Grant	Grant Utility: Stable liquid vaccinia virus formulations Filling date: 1 Dec 2015 Issue date: 31 Dec 2019	1 Dec 2015	31 Dec 2019
Application	Application ONCOLYTIC VIRUSES AND THERAPEUTIC MOLECULES Filling date: 21 Dec 2017 Issue date: 31 Oct 2019	21 Dec 2017	31 Oct 2019
Application	Application IMMUNOTHERAPEUTIC PRODUCT AND MDSC MODULATOR COMBINATION THERAPY Filling date: 10 Oct 2017 Issue date: 31 Oct 2019	10 Oct 2017	31 Oct 2019

Transgene SA
Executives

Insider	Age	Compensation
Dr. Philippe Archinard Ph.D. (1959) Chairman & Chief Executive Officer	66	$746,000
Mr. Christophe Ancel (1965) Deputy Chief Executive Officer & Vice President of Quality	60	$144,000
Lucie Larguier Director of Corporation Communications & IR
Mr. Philippe Slos Head of Preclinical Regulatory Laboratory
Mr. Thibaut du Fayet Vice President of Strategic Alliance, Project Management & Marketing
Mr. Jean-Philippe Del Chief Financial Officer & Vice President of Fin.
Ms. Elisabetta Castelli Director of Investor Relations
Dr. Éric Quéméneur Executive Vice President and Vice President of R&D
Mr. John Felitti Vice President, Gen. Counsel & Corporation Sec.
Dr. Maud Brandely-Talbot Chief Medical Officer

Frequently Asked Questions (FAQ)

What's the price of Transgene SA stock today?

One share of Transgene SA stock can currently be purchased for approximately $3.04.
When is Transgene SA's next earnings date?

Unfortunately, Transgene SA's (0OCQ.L) next earnings date is currently unknown.
Does Transgene SA pay dividends?

No, Transgene SA does not pay dividends.
How much money does Transgene SA make?

Transgene SA has a market capitalization of 93.42M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 62.12% to 1.18M US dollars.
What is Transgene SA's stock symbol?

Transgene SA is traded on the LSE under the ticker symbol "0OCQ.L".
What is Transgene SA's primary industry?

Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
How do i buy shares of Transgene SA?

Shares of Transgene SA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Transgene SA's key executives?
Transgene SA's management team includes the following people:
- Dr. Philippe Archinard Ph.D. Chairman & Chief Executive Officer(age: 66, pay: $746,000)
- Mr. Christophe Ancel Deputy Chief Executive Officer & Vice President of Quality(age: 60, pay: $144,000)
- Lucie Larguier Director of Corporation Communications & IR
- Mr. Philippe Slos Head of Preclinical Regulatory Laboratory
- Mr. Thibaut du Fayet Vice President of Strategic Alliance, Project Management & Marketing
- Mr. Jean-Philippe Del Chief Financial Officer & Vice President of Fin.
- Ms. Elisabetta Castelli Director of Investor Relations
- Dr. Éric Quéméneur Executive Vice President and Vice President of R&D
- Mr. John Felitti Vice President, Gen. Counsel & Corporation Sec.
- Dr. Maud Brandely-Talbot Chief Medical Officer
How many employees does Transgene SA have?

As Jul 2024, Transgene SA employs 141 workers, which is 1% less then previous quarter.
When Transgene SA went public?

Transgene SA is publicly traded company for more then 16 years since IPO on 5 Nov 2008.
What is Transgene SA's official website?

The official website for Transgene SA is transgene.fr.
How can i contact Transgene SA?

Transgene SA can be reached via phone at +33 3 88 27 91 00.

Transgene SA

transgene.fr

Exchange:

LSE

Full time employees:

146

Industry:

Medical - Pharmaceuticals

Sector:

Healthcare

Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. It is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative head and neck cancers; TG4001, a therapeutic vaccine, which is in phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in phase I/IIa clinical trial for the treatment of various solid tumors, such as gastrointestinal adenocarcinoma comprising stomach, pancreas, and colon; and BT-001, an oncolytic virus, which is in phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Sanofi, BioInvent, and Randox. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.

+33 3 88 27 91 00

400, Boulevard Gonthier d’Andernach
Illkirch-Graffenstaden, 67405

:
ISIN: FR0005175080
: